Artwork

Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Oncology Grand Rounds Series: Part 3 — Locally Advanced Non-Small Cell Lung Cancer

1:23:58
 
Share
 

Manage episode 236844555 series 1464352
Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Video proceedings from the third in a series of 6 integrated symposia held at the 2019 ONS Annual Congress. Featuring perspectives from Dr Edward B Garon, Dr Matthew Gubens, Ms Blanca Ledezma and Ms Wendi S Lee.

  • Introduction (0m0s)
    • Program overview: Dr Love
  • Historical Treatment Paradigms and Related Outcomes for Patients with Stage III Non-Small Cell Lung Cancer (NSCLC); Biologic Rationale for the Evaluation of Immune Checkpoint Inhibitors in This Setting (00:54)
  • Case (Ms Lee): A woman in her early 70s with Stage IIIA adenocarcinoma of the lung who received concurrent chemoradiation therapy and developed Grade 2 esophagitis (1:16)
  • Available Efficacy Data with and Indications for Durvalumab Consolidation in Unresectable Stage III Disease (16:22)
  • Case (Ms Ledezma): A man in his early 70s who received chemoradiation therapy and consolidation durvalumab for new primary Stage III NSCLC after undergoing treatment for Stage IIIB disease 10 years prior (16:34)
  • Case (Ms Lee): A woman in her early 70s with Stage IIIB adenocarcinoma of the lung who underwent concurrent chemoradiation therapy followed by durvalumab consolidation (28:59)
  • Incidence, Recognition and Management of Immune-Mediated and Other Toxicities Associated with the Use of Durvalumab in Unresectable Stage III Disease (55:03)
  • Case (Ms Ledezma): A man in his mid-70s with Stage IIIA NSCLC who enrolled on a clinical trial of neoadjuvant atezolizumab and developed pneumonitis (1:8:31)
  • Case (Ms Ledezma): A woman in her early 50s who was found to have a Stage III adenocarcinoma of the lung with an EGFR tumor mutation while undergoing workup for breast cancer and received chemoradiation therapy and durvalumab consolidation (1:13:58)
  • Case (Ms Lee): A man in his 50s with Stage IIIA adenocarcinoma of the lung who received chemoradiation therapy and consolidation durvalumab after undergoing lobectomy (1:17:10)

Select publications

  continue reading

1407 episodes

Artwork
iconShare
 
Manage episode 236844555 series 1464352
Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Video proceedings from the third in a series of 6 integrated symposia held at the 2019 ONS Annual Congress. Featuring perspectives from Dr Edward B Garon, Dr Matthew Gubens, Ms Blanca Ledezma and Ms Wendi S Lee.

  • Introduction (0m0s)
    • Program overview: Dr Love
  • Historical Treatment Paradigms and Related Outcomes for Patients with Stage III Non-Small Cell Lung Cancer (NSCLC); Biologic Rationale for the Evaluation of Immune Checkpoint Inhibitors in This Setting (00:54)
  • Case (Ms Lee): A woman in her early 70s with Stage IIIA adenocarcinoma of the lung who received concurrent chemoradiation therapy and developed Grade 2 esophagitis (1:16)
  • Available Efficacy Data with and Indications for Durvalumab Consolidation in Unresectable Stage III Disease (16:22)
  • Case (Ms Ledezma): A man in his early 70s who received chemoradiation therapy and consolidation durvalumab for new primary Stage III NSCLC after undergoing treatment for Stage IIIB disease 10 years prior (16:34)
  • Case (Ms Lee): A woman in her early 70s with Stage IIIB adenocarcinoma of the lung who underwent concurrent chemoradiation therapy followed by durvalumab consolidation (28:59)
  • Incidence, Recognition and Management of Immune-Mediated and Other Toxicities Associated with the Use of Durvalumab in Unresectable Stage III Disease (55:03)
  • Case (Ms Ledezma): A man in his mid-70s with Stage IIIA NSCLC who enrolled on a clinical trial of neoadjuvant atezolizumab and developed pneumonitis (1:8:31)
  • Case (Ms Ledezma): A woman in her early 50s who was found to have a Stage III adenocarcinoma of the lung with an EGFR tumor mutation while undergoing workup for breast cancer and received chemoradiation therapy and durvalumab consolidation (1:13:58)
  • Case (Ms Lee): A man in his 50s with Stage IIIA adenocarcinoma of the lung who received chemoradiation therapy and consolidation durvalumab after undergoing lobectomy (1:17:10)

Select publications

  continue reading

1407 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide